

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
04 September 2025 (04.09.2025)



(10) International Publication Number
WO 2025/184482 A1

(51) International Patent Classification:

A61K 31/395 (2006.01) *A61K 31/445* (2006.01)
A61K 31/505 (2006.01) *A61K 31/33* (2006.01)
A61K 31/13 (2006.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(21) International Application Number:

PCT/US2025/017809

(22) International Filing Date:

28 February 2025 (28.02.2025)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/559,837 29 February 2024 (29.02.2024) US

(71) Applicant: **TELIOS PHARMA, INC.** [US/US]; 275
Shoreline Drive, Suite 325, Redwood City, California 94065
(US).

(72) Inventor: **ROTHBAUM, Wayne**; 101 Central Park West,
Suite 1F, New York, New York 10023 (US).

(74) Agent: **PLUMMER, Kelly** et al.; c/o Morgan, Lewis &
Bockius LLP, 1111 Pennsylvania Ave NW, Washington,
District of Columbia 20004 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN,
WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC DISEASE

(57) Abstract: Therapeutic methods and ophthalmic compositions for reducing ocular mast cell degranulation and/or ocular mast cell cytokine production in a human subject, inhibiting ocular mast cell activation in a human subject, treating dry eye disease (DED) or allergic conjunctivitis (AC) in a human subject, inhibiting mast cell activation in a human subject, and reducing or alleviating a sign or symptom of dry eye disease in a human subject using a BTK inhibitor are described. The disclosure also includes therapeutic methods and ophthalmic compositions for reducing or alleviating a sign or symptom of allergic conjunctivitis in a human subject and treating allergic conjunctivitis in a human subject using a BTK inhibitor.



WO 2025/184482 A1